Theravance Biopharma (TBPH) Accumulated Depreciation & Amortization (2013 - 2025)

Theravance Biopharma (TBPH) has 13 years of Accumulated Depreciation & Amortization data on file, last reported at $23.8 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 6.34% year-over-year to $23.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.8 million (up 6.34% YoY) and the FY2025 annual result came in at $23.8 million, up 6.34% from the prior year.
• Accumulated Depreciation & Amortization climbed to $23.8 million in Q4 2025 per TBPH's latest filing, from $22.4 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $38.5 million in Q4 2021 and bottomed at $21.6 million in Q4 2023.
• The 5-year median for Accumulated Depreciation & Amortization is $23.8 million (2025), against an average of $27.8 million.
• The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization plunged 34.27%; it then increased 6.34% in 2025.
• Tracing TBPH's Accumulated Depreciation & Amortization over 5 years: stood at $38.5 million in 2021, then dropped by 14.69% to $32.8 million in 2022, then sank by 34.27% to $21.6 million in 2023, then climbed by 3.79% to $22.4 million in 2024, then grew by 6.34% to $23.8 million in 2025.
• Per Business Quant, the three latest TBPH Accumulated Depreciation & Amortization figures stand at $23.8 million (Q4 2025), $22.4 million (Q4 2024), and $21.6 million (Q4 2023).

Peer Comparison